Video
Elran Haber, CEO at Biomica Ltd, discussed the emerging role of microbiome-based treatments in cancer care.
Johan van Hylckama Vlieg, CSO and Co-founder of Freya Biosciences, discusses the latest advancements in microbial immunotherapies for women's health.
Maria Lluch Senar, Founder and Chief Scientific Officer at Pulmobiotics SL, discusses the research on engineering Live Biotherapeutics in order to expose antigens or deliver therapeutic agents to treat complex…
Shahram Lavasani, Founder & CEO at ImmuneBiotech AB, discusses the recent data about gut microbiota and Pre-eclampsia.
Giovanni Barbara, congress chair, explain why it is important to be part of IBS Days 2024.
Alessio Fasano gives an overview of the IHMC Congress to be held in Rome, 22-25 June.
Silvia Barbaresi, molecular biologist, researcher and nutritionist at Ghent Univerity, discusses how sports and physical activity in general impact on gut microbiota composition.
Alessio Fasano, pediatric gastroenterologist and researcher at Harvard Medical School, discusses how celiac disease could become a model to study the link between gut microbiome and disease pathogenesis.
Gianluca Ianiro, from Gemelli Hospital in Rome, discusses the future of microbiota modulation, with a focus on Microbial Therapeutics.
Francisco Guarner, from Centro Médico Teknon (Barcelona, Spain), talks about the recent update of the WGO’s Probiotics and prebiotics guidelines.
